



Policy Name	Policy Number	Scope
Telisotuzumab vedotin-tllv (Emrelis)	MP-RX- FP-175-25	<input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM Multihealth
<p>1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, for example, light housework, office work</p> <p>2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours</p> <p>3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours</p> <p>4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair</p> <p>5 = Dead</p> <p>Line of Therapy:            First-line therapy: The first or primary treatment for the diagnosis, which may include surgery, chemotherapy, radiation therapy or a combination of these therapies.</p> <p>Second-line therapy: Treatment given when initial treatment (first-line therapy) is not effective or there is disease progression.</p> <p>Third-line therapy: Treatment given when both initial (first-line therapy) and subsequent treatment (second-line therapy) are not effective or there is disease progression.</p> <p>Locally advanced cancer: Cancer that has spread only to nearby tissues or lymph nodes.</p> <p>Maintenance therapy: Designed to maintain a condition to prevent a relapse.</p> <p>Malignant: Cancerous. Malignant cells can invade and destroy nearby tissue and spread to other parts of the body.</p> <p>Metastasis: The spread of cancer from one part of the body to another; a metastatic tumor contains cells that are like those in the original (primary) tumor and have spread.</p> <p>Mutation: A permanent, transmissible change in genetic material.</p> <p>Non-small cell lung cancer: A group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma.</p> <p>One line of therapy: Single line of therapy.</p>		

# Medical Policy

Healthcare Services Department

Policy Name	Policy Number	Scope
Telisotuzumab vedotin-tllv (Emrelis)	MP-RX- FP-175-25	<input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM Multihealth
<p>Primary refractory disease: Cancer that does not respond at the beginning of treatment; may also be called resistant disease.</p> <p>Primary treatment: The first treatment given for a disease. It is often part of a standard set of treatments, such as surgery followed by chemotherapy and radiation. Also called first-line therapy, induction therapy, and primary therapy.</p> <p>Progressive Disease (PD): Cancer is growing, spreading, or getting worse. Refractory Disease: Illness or disease that does not respond to treatment.</p> <p>Relapses or recurrence: After a period of improvement, during which time a disease (for example, cancer) could not be detected, the return of signs and symptoms of illness or disease. For cancer, it may come back to the same place as the original (primary) tumor or to another place in the body.</p> <p>Stable disease: Cancer that is not decreasing or increasing in extent or severity.</p> <p>Targeted biologic agent: A newer type of drug developed specifically to target genetic changes in cells that cause cancer. It works differently than standard chemotherapy drugs, often with different side effects.</p>		

# Medical Policy

Healthcare Services Department

<b>Policy Name</b>	<b>Policy Number</b>	<b>Scope</b>				
Telisotuzumab vedotin-tllv (Emrelis)	MP-RX- FP-175-25	<input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM Multihealth				
<b>Applicable Codes</b>						
<p>The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.</p>						
<table border="1"> <thead> <tr> <th data-bbox="154 714 414 745">HCPCS</th> <th data-bbox="414 714 1469 745">Description</th> </tr> </thead> <tbody> <tr> <td data-bbox="154 745 414 787">J9326</td> <td data-bbox="414 745 1469 787">Injection Telisotuzumab Vedotin-Tllv 1 Mg</td> </tr> </tbody> </table>			HCPCS	Description	J9326	Injection Telisotuzumab Vedotin-Tllv 1 Mg
HCPCS	Description					
J9326	Injection Telisotuzumab Vedotin-Tllv 1 Mg					
<table border="1"> <thead> <tr> <th data-bbox="154 819 414 850">ICD-10</th> <th data-bbox="414 819 1469 850">Description</th> </tr> </thead> <tbody> <tr> <td data-bbox="154 850 414 892"></td> <td data-bbox="414 850 1469 892">All diagnosis pend.</td> </tr> </tbody> </table>			ICD-10	Description		All diagnosis pend.
ICD-10	Description					
	All diagnosis pend.					

## Medical Necessity Guidelines

When a drug is being reviewed for coverage under a member's medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

### Telisotuzumab vedotin-tllv (Emrelis)

Requests for Emrelis (telisotuzumab vedotin-tllv) may be approved if the following criteria are met:

#### A. Criteria For Initial Approval

- i. Individual has a diagnosis of Non-small cell lung cancer (NSCLC) (Label, NCCN 2A); **AND**
- ii. Individual has advanced or metastatic non-squamous (EGFR wild-type) NSCLC; **AND**
- iii. Individual has high c-Met/MET protein expression [ $\geq$  50% of tumor cells with strong (IHC 3+) staining]; **AND**
- iv. Individual has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2; **AND**
- v. Individual has received a prior systemic therapy.

#### B. Criteria For Continuation of Therapy

- I. MMM considers continuation of Telisotuzumab vedotin-tllv (Emrelis) therapy medically necessary in members requesting reauthorization for an indication listed in Section A above (Criteria for Initial Approval) when there is no evidence of unacceptable toxicity or disease progression while on the current regimen, and the recommended duration of therapy has not been exceeded. The following information should be submitted for reauthorization:
  - a. *A current oncology note documenting the patient's response to treatment showing no progression of disease*
  - b. *. B. Current imaging studies and other objective measures, as appropriate, showing no progression of disease when compared with previous results*

#### C. Authorization Duration

- a. Initial Approval Duration: up to 6 months
- b. Reauthorization Approval Duration: up to 6 months

#### D. Conditions Not Covered

*Any other use is considered experimental, investigational, or unproven, including the following (this list may not be all inclusive):*

- i. Individual has moderate or severe hepatic impairment (total bilirubin  $>$  1.5 x ULN and any AST); **OR**
- ii. When the above criteria are not met and for all other indications.

Policy Name	Policy Number	Scope
Telisotuzumab vedotin-tllv (Emrelis)	MP-RX- FP-175-25	<input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM Multihealth

### Limits or Restrictions

#### A. Quantity Limitations

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines. The chart below includes dosing recommendations as per the FDA-approved prescribing information.

Drug	Vials
EMRELIS (telisotuzumab vedotin-tllv)-for injection	<ul style="list-style-type: none"> <li>Intravenous Solution Reconstituted 100MG Vial</li> <li>Intravenous Solution Reconstituted 20MG Vial</li> </ul>
Dosage	
1.9 mg/kg (up to a maximum of 190 mg for patients greater than or equal to 100 kg) administered as an intravenous infusion over 30 minutes every 2 weeks until disease progression or unacceptable toxicity	

### Reference Information

1. Clinicaltrials.gov. National Library of Medicine. Available at: <https://clinicaltrials.gov/>. Accessed on May 27, 2025.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: May 27, 2025.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. NCCN Clinical Practice Guidelines in Oncology™. © 2025 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on May 27, 2025.

Non-Small Cell Lung Cancer. V4.2025. Revised May 23, 2025

# Medical Policy

Healthcare Services Department

<b>Policy Name</b> Telisotuzumab vedotin-tllv (Emrelis)	<b>Policy Number</b> MP-RX- FP-175-25	<b>Scope</b> <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM Multihealth
--	--	--

## Policy History

Revision Type	Summary of Changes	P&T Approval Date	MPCC Approval Date
Select Review 1/7/2026	Coding reviewed: J9326 added.	N/A	N/A
Policy Inception 7/11/2025	Elevance Health's Medical Policy adoption.	7/21/2025	8/8/2025